NASDAQ:INAB IN8bio (INAB) Stock Price, News & Analysis $2.35 -0.04 (-1.67%) Closing price 04:00 PM EasternExtended Trading$2.32 -0.03 (-1.45%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IN8bio Stock (NASDAQ:INAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IN8bio alerts:Sign Up Key Stats Today's Range$2.33▼$2.4350-Day Range$1.91▼$2.4052-Week Range$1.91▼$16.70Volume52,182 shsAverage Volume79,368 shsMarket Capitalization$10.67 millionP/E RatioN/ADividend YieldN/APrice Target$180.00Consensus RatingHold Company Overview IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline. IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications. Its memory T cell platform targets neuroinflammation and has produced product candidates for acute ischemic stroke and Alzheimer’s disease, with preclinical and translational data supporting potential disease-modifying effects. Headquartered in South San Francisco, California, IN8bio was previously known as INmune Bio before its name change in late 2021. The company maintains collaborations with academic and clinical institutions across the United States to advance its research programs. Led by an experienced management team with backgrounds in cell therapy and drug development, IN8bio continues to build its infrastructure for manufacturing, regulatory engagement and clinical execution in pursuit of first-in-class immunotherapies.AI Generated. May Contain Errors. Read More IN8bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreINAB MarketRank™: IN8bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 654th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingIN8bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialIN8bio has a consensus price target of $180.00, representing about 7,559.6% upside from its current price of $2.35.Amount of Analyst CoverageIN8bio has only been the subject of 1 research reports in the past 90 days.Read more about IN8bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about IN8bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.62% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently increased by 42.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.62% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently increased by 42.48%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows2 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of IN8bio is held by insiders.Percentage Held by Institutions92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IN8bio's insider trading history. Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INAB Stock News HeadlinesIn8bio, Inc. Reports Improved Financial PerformanceAugust 18, 2025 | theglobeandmail.comIN8bio (INAB) Q2 Loss Narrows 77%August 18, 2025 | theglobeandmail.comClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...October 6 at 2:00 AM | Angel Publishing (Ad)IN8bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | globenewswire.comIN8bio, Inc. (INAB) stock price, news, quote & history – Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comIN8bio Regains Nasdaq Compliance with Bid Price RuleJune 30, 2025 | tipranks.comIN8bio, Inc: IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialJune 9, 2025 | finanznachrichten.deIN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialJune 9, 2025 | globenewswire.comSee More Headlines INAB Stock Analysis - Frequently Asked Questions How have INAB shares performed this year? IN8bio's stock was trading at $7.7160 on January 1st, 2025. Since then, INAB stock has decreased by 69.5% and is now trading at $2.35. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.26. When did IN8bio's stock split? IN8bio shares reverse split on Friday, June 6th 2025.The 1-30 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did IN8bio IPO? IN8bio (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IN8bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META). Company Calendar Last Earnings8/07/2025Today10/06/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INAB CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees20Year Founded2016Price Target and Rating Average Price Target for IN8bio$180.00 High Price Target$180.00 Low Price Target$180.00 Potential Upside/Downside+7,447.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($9.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-184.97% Return on Assets-126.75% Debt Debt-to-Equity Ratio0.01 Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.00 per share Price / Book0.40Miscellaneous Outstanding Shares4,540,000Free Float4,109,000Market Cap$10.83 million OptionableNot Optionable Beta0.03 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:INAB) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredOctober 2025 Market Crash?Wall Street Legend Names #1 Stock [not NVDA] The greatest quantitative mind on Wall Street just revealed hi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.